Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/24/2022* -- Results Q4 2021 -- 0.31 --
02/24/2022* 09:00 EST Earnings Call Q4 2021 -- -- --
11/03/2021 -- Results Q3 2021 -0.34 -0.32 -5.30%
11/03/2021 11:30 EST Earnings Call Q3 2021 -- -- --
08/04/2021 -- Results Q2 2021 -0.26 -0.32 19.02%
08/04/2021 11:30 EST Earnings Call Q2 2021 -- -- --
05/05/2021 -- Results Q1 2021 -0.32 -0.25 -25.57%
05/05/2021 11:30 EST Earnings Call Q1 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 02/24/2022
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/03/2021
Beat/Miss Upgrade
Return Since -6.99%
Last FQE 09/30/2021
Next FQE 12/30/2021

Profile

Edit
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
URL https://www.ionispharma.com
Investor Relations URL https://ir.ionispharma.com
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Feb. 24, 2022
Last Earnings Release Nov. 03, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
0.31%
-22.77%
5.16%
7.48%
11.75%
-6.41%
-46.18%
3.19%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-7.41%
-9.75%
-7.43%
21.96%
-5.54%
-1.39%
-17.48%
-2.02%
-6.35%
--
--
--
--
28.09%
434.1%
143.1%
-38.07%
5.92%
-41.45%
103.4%
10.58%
32.13%
7.94%
-7.08%
4.59%
-24.71%
-21.82%
-71.84%
-75.28%
-9.78%
16.91%
-52.07%
-16.36%
As of January 24, 2022.

Profile

Edit
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
URL https://www.ionispharma.com
Investor Relations URL https://ir.ionispharma.com
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Feb. 24, 2022
Last Earnings Release Nov. 03, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
ARKG 199.19M USD 5.26%
FBT 52.89M USD 3.44%
CIG4924 6.196M USD 3.43%
SBIO 4.798M USD 3.34%
KRXCX 268320.0 USD 1.47%
CHCRFX 144.00 USD 1.44%
AASMX 21.19M USD 1.44%
TGFRX 262018.0 USD 1.06%
HQL 5.239M USD 0.99%
XBI 54.81M USD 0.98%
LABU 6.741M USD 0.92%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Stocktwits IONS Tweets